New study tracks bleeding prevention in kids with hemophilia a
NCT ID NCT07088458
First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 27 times
Summary
This study observes children aged 7 to 12 with hemophilia A who are already prescribed damoctocog alfa pegol, a medicine that replaces missing clotting factor. Researchers will collect data from routine care over two years to see how well the drug prevents bleeding episodes. No extra tests or visits are required—parents keep a diary of bleeds and treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.